Prenatal Monitoring of Perinatal Pregnant Women and Fetus Based on a Smart Electronic Fetal Monitoring System.

The aim of the study is to study the prenatal monitoring of perinatal pregnant women based on a smart electronic fetal monitoring system. Through the comparative analysis of 230 pregnant women in maternal and child health care hospital who received fetal heart monitoring during the perinatal period and those who did not receive fetal heart monitoring during the perinatal period, cases of fetal distress, neonatal asphyxia, and cesarean section were observed in both groups. Results show that the incidences of fetal complications and cesarean sections in the experimental group were 16.36% and 36.82%, which was significantly higher than 4.50% and 17.50% in the control group(p < 0.05); the neonatal mild and severe asphyxia rates in the experimental group were 3.18% and 1.36%, which were significantly lower than 9.50% and 6.50% in the control group (p < 0.05). The experimental results show that the correct application of fetal heart rate monitoring in the perinatal period can aid in early detection and dealing with fetal distress and reduce the occurrence of various complications such as neonatal asphyxia. It is worthy to be popularized and applied in clinics.

Tenofovir alafenamide in blocking mother-to-child transmission of hepatitis B virus: a multi-center, prospective study.

BACKGROUND: Data of tenofovir alafenamide (TAF) in preventing mother-to-child transmission (MTCT) of hepatitis B virus (HBV) are limited. This study aimed to evaluate the effectiveness and safety of TAF for preventing MTCT. METHODS: Pregnant women with chronic HBV infection, positive for HBeAg and high-level HBV DNA, received oral TAF from gestational weeks 24-28 until postpartum week 4. All infants received HBV immunoprophylaxis. All mothers and infants were followed up until postpartum seven month. The primary outcome was the rate of MTCT at seven month. RESULTS: Eighty-nine mothers delivered and 91 infants were born. All were followed up to postpartum seven month. TAF was initiated at a mean gestational age of 25.0 (±1.0) weeks with the mean treatment duration of 14.3 (±1.2) weeks before delivery; 92.1% (82/89) mothers discontinued TAF, the median [IQR] time was 5.9 [4.7] weeks postpartum. The HBsAg positive rate was 0% at seven months in 91 infants, no growth retardation and congenital defects. All mothers were tolerated during TAF treatment. At delivery, 82.02% (73/89) mothers achieved HBV DNA < 200,000 IU/ml, 21.35% (19/89) achieved HBV DNA < 500 IU/ml. No significant changes on the mean (±SD) serum phosphate between baseline (1.20 ± 0.10 mmol/L) and at delivery (1.21 ± 0.13 mmol/L, p > .05). Serum creatinine at delivery (52.23 ± 8.50 µmol/L) was higher than baseline (45.97 ± 5.60 µmol/L, p < .05), but within normal range. Nine of 82 mothers stopped TAF treatment after delivery had mild ALT elevation. CONCLUSION: TAF therapy initiated during the second trimester was effective in preventing MTCT with no safety concerns for mothers and infants (ClinicalTrials.gov number, NCT04065230).